Harmony Biosciences Holdings annual return on equity
2021
2022
2023
2024
2025
Harmony Biosciences Holdings Return on Equity (ROE) Growth & History (HRMY)
Harmony Biosciences Holdings's return on equity was 20.75% for fiscal 2025.
View full Harmony Biosciences Holdings company overviewHarmony Biosciences Holdings annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 20.75% | −5.09 pp |
| 2024 | 2024-12-31 | 25.84% | −3.79 pp |
| 2023 | 2023-12-31 | 29.63% | −31.96 pp |
| 2022 | 2022-12-31 | 61.58% | +37.19 pp |
| 2021 | 2021-12-31 | 24.39% | — |
Harmony Biosciences Holdings quarterly return on equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 7.90% | +2.57 pp |
| Q1 2026 | 2026-03-31 | 3.65% | −2.96 pp |
| Q4 2025 | 2025-12-31 | 2.64% | −5.24 pp |
| Q3 2025 | 2025-09-30 | 6.33% | −1.79 pp |
| Q2 2025 | 2025-06-30 | 5.33% | +3.13 pp |
| Q1 2025 | 2025-03-31 | 6.60% | −1.20 pp |
| Q4 2024 | 2024-12-31 | 7.88% | +2.27 pp |
| Q3 2024 | 2024-09-30 | 8.12% | +0.16 pp |
| Q2 2024 | 2024-06-30 | 2.20% | −5.19 pp |
| Q1 2024 | 2024-03-31 | 7.80% | +0.83 pp |
| Q4 2023 | 2023-12-31 | 5.61% | −7.38 pp |
| Q3 2023 | 2023-09-30 | 7.96% | −21.83 pp |
| Q2 2023 | 2023-06-30 | 7.39% | −2.82 pp |
| Q1 2023 | 2023-03-31 | 6.97% | −3.74 pp |
| Q4 2022 | 2022-12-31 | 12.99% | −0.43 pp |
| Q3 2022 | 2022-09-30 | 29.79% | +36.70 pp |
| Q2 2022 | 2022-06-30 | 10.21% | −1.84 pp |
| Q1 2022 | 2022-03-31 | 10.72% | +3.51 pp |
| Q4 2021 | 2021-12-31 | 13.42% | +13.63 pp |
| Q3 2021 | 2021-09-30 | −6.91% | — |
| Q2 2021 | 2021-06-30 | 12.04% | — |
| Q1 2021 | 2021-03-31 | 7.20% | — |
| Q4 2020 | 2020-12-31 | −0.21% | — |
Harmony Biosciences Holdings return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Harmony Biosciences Holdings's return on equity decreased from 24.39% to 20.75%, a change of −3.64 percentage points. The latest reported quarter, Q2 2026, shows 7.90%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Harmony Biosciences Holdings source filings ↗